Naquila, Madelyn C.
HRN: 23 06 49 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/29/2023
CO-AMOXICLAV 625MG (TAB)
05/29/2023
06/05/2023
PO
625mg
BID
Empiric
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & MouthMultiple Infections (tick All Sites) Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes